RYTM.OQ - Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc
Needham & Company Inc.Price Target Decrease

High Risk Ph3 EMANATE Trial Misses, But Thesis Still Intact. Lower PT to $130.

公司
RYTM.OQ
日期
2026-03-17
分析师
Mr. Joseph Stringer, PHD
页数
11
需要登录
请登录后购买研报或生成音频内容。